ProMIS Neurosciences' PMN310 Shows Dose-Dependent Reduction Of Amyloid-Beta Oligomers In Healthy Volunteers, With Six-Month Phase 1b Interim Data Expected Soon

ProMIS Neurosciences Inc.

ProMIS Neurosciences Inc.

PMN

0.00
  • PMN310 demonstrated dose-dependent reduction of amyloid-beta oligomers in human cerebrospinal fluid following a single dose in healthy volunteers
  • Represents one of the first quantitative measures of treatment-related effects on oligomer levels in a clinical trial
  • Company on track to present six-month blinded interim data from its Phase 1b trial in the coming weeks
  • Poster to be presented today, July 14, at the 2026 Alzheimer’s Association International Conference® (AAIC)
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.